Executive summary of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer
Felipe Villar Álvarez 1 , Ignacio Muguruza Trueba 2 , José Belda Sanchis 3 , Laureano Molins López-Rodó 4 , Pedro Miguel Rodríguez Suárez 5 , Julio Sánchez de Cos Escuín 6 , Esther Barreiro 7 , M Henar Borrego Pintado 8 , Carlos Disdier Vicente 9 , Javier Flandes Aldeyturriaga 10 , Pablo Gámez García 11 , Pilar Garrido López 12 , Pablo León Atance 13 , José Miguel Izquierdo Elena 14 , Nuria M Novoa Valentín 15 , Juan José Rivas de Andrés 16 , Íñigo Royo Crespo 16 , Ángel Salvatierra Velázquez 17 , Luís M Seijo Maceiras 18 , Segismundo Solano Reina 19 , David Aguiar Bujanda 20 , Régulo J Avila Martínez 11 , Jose Ignacio de Granda Orive 21 , Eva de Higes Martinez 22 , Vicente Diaz-Hellín Gude 11 , Raúl Embún Flor 16 , Jorge L Freixinet Gilart 5 , María Dolores García Jiménez 13 , Fátima Hermoso Alarza 11 , Samuel Hernández Sarmiento 20 , Antonio Francisco Honguero Martínez 13 , Carlos A Jimenez Ruiz 23 , Iker López Sanz 14 , Andrea Mariscal de Alba 11 , Primitivo Martínez Vallina 16 , Patricia Menal Muñoz 24 , Laura Mezquita Pérez 12 , María Eugenia Olmedo García 12 , Carlos A Rombolá 13 , Iñigo San Miguel Arregui 25 , María de Valle Somiedo Gutiérrez 10 , Ana Isabel Triviño Ramírez 13 , Joan Carles Trujillo Reyes 3 , Carmen Vallejo 26 , Paz Vaquero Lozano 19 , Gonzalo Varela Simó 15 , Javier J Zulueta 27
The Thoracic Surgery and Thoracic Oncology groups of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) have backed the publication of a handbook on recommendations for the diagnosis and treatment of non-small cell lung cancer. Due to the high incidence and mortality of this disease, the best scientific evidence must be constantly updated and made available for consultation by healthcare professionals.
To draw up these recommendations, we called on a wide-ranging group of experts from the different specialties, who have prepared a comprehensive review, divided into 4 main sections. The first addresses disease prevention and screening, including risk factors, the role of smoking cessation, and screening programs for early diagnosis. The second section analyzes clinical presentation, imaging studies, and surgical risk, including cardiological risk and the evaluation of respiratory function. The third section addresses cytohistological confirmation and staging studies, and scrutinizes the TNM and histological classifications, non-invasive and minimally invasive sampling methods, and surgical techniques for diagnosis and staging. The fourth and final section looks at different therapeutic aspects, such as the role of surgery, chemotherapy, radiation therapy, a multidisciplinary approach according to disease stage, and other specifically targeted treatments, concluding with recommendations on the follow-up of lung cancer patients and surgical and endoscopic palliative interventions in advanced stages.
CITATION Arch Bronconeumol. 2016 Jul;52(7):378-88. doi: 10.1016/j.arbres.2016.02.016. Epub 2016 May 27